When was Vandria founded?

Vandria was founded in 2018 and raised its 1st funding round 5 years after it was founded.

Where is Vandria located?

Vandria is headquartered in Lausanne, Switzerland.

How many employees does Vandria have?

As of Aug 31, 2026, the latest employee count at Vandria is 16.

Is Vandria a funded company?

Vandria is a funded company, having raised a total of $30.7M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 14, 2023.

When was the latest funding round of Vandria?

Vandria's latest funding was a $***** Series A round on Aug 23, 2024, with participation from 3 investors.

Where does Vandria rank among its competitors?

Vandria ranks 211th amongst 2604 active competitors, of which 887 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Vandria?

Vandria's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Vandria - 2026 Company Profile, Team, Funding & Competitors

Vandria is a series A company based in Lausanne (Switzerland), founded in 2018 by Patrick Aebischer and Chris Rinsch. It operates as a Developer of in-vitro screening platform for drug discovery and development. Vandria has raised $30.7M in funding from investors like Dolby Family Ventures, Hevolution and ND Capital. The company has 2604 active competitors, including 887 funded and 649 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of in-vitro screening platform for drug discovery and development. The company has created a platform for identifying and discovering small compounds (mitophagy inducers). It aids in the identification of the leading candidate molecule linked to age-related and chronic diseases.

Website: vandria.com
Email ID: *****@vandria.com

Key Metrics

Founded Year

2018

Location

Lausanne, Switzerland

Stage

Series A

Total Funding

$30.7M in 2 rounds

Latest Funding Round

Series A, Aug 23, 2024, $*****

Investors

Dolby Family Ventures & 2 more

Ranked

211^th among 2604 active competitors

Employee Count

16 as on Aug 31, 2026

Similar Companies

4D Molecular Therapeutics & 134 more

View Vandria's full profile

Vandria has raised a total funding of $30.7M over 2 rounds. Its first funding round was on Dec 14, 2023. Its latest funding round was a Series A round on Aug 23, 2024 for $*****. 3 investors participated in its latest round. Vandria has 3 institutional investors.

Here is the list of recent funding rounds of Vandria:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 23, 2024	2760985	Series A	8434198	5154781	5667827	3878623
Dec 14, 2023	2972315	Series A	5174056	8952574	ND Capital	9824382

Access funding benchmarks and valuations. Sign up today!

View details of Vandria's funding rounds and investors

The founders of Vandria are Patrick Aebischer and Chris Rinsch.

Here are the details of Vandria's key team members:

Patrick Aebischer: Co-Founder of Vandria.
Contact Info: 3 email addresses
Chris Rinsch: Co-Founder of Vandria.

View details of Vandria's Founder profiles and Board Members

Vandria's employee count trend

Vandria has 16 employees as of Aug 26. Here is Vandria's employee count trend over the years:

Uncover Vandria's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vandria include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Vandria, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
211th	Vandria 2018, Lausanne (Switzerland), Series A	Developer of in-vitro screening platform for drug discovery and development	$30.7M	ND Capital, Dolby Family Ventures & 1 others	58/100